Эффективность и безопасность ингибиторов янускиназ в лечении гнездной алопеции у детей

Гнездная алопеция – аутоиммунное воспалительное заболевание, характеризующееся нерубцовым выпадением волос. Представленный обзор систематизирует современные данные о патогенезе заболевания и эффективности системной терапии JAK-ингибиторами в педиатрической практике. Особое внимание уделено селективным препаратам и их безопасности у детей с тяжёлыми формами гнездной алопеции.

1. Alkhalifah A. Alopecia areata update. Dermatologic Clinics. 2013; 31 (1): 93–108.

2. Rangu S., Rogers R., Castelo-Soccio L. Understanding alopecia areata characteristics in children under the age of 4 years. Pediatric Dermatology. 2019; 36 (6): 854–858.

3. Lintzeri D.A., Constantinou A., Hillmann K., et al. Alopecia areata – current understanding and management. Journal der Deutschen Dermatologischen Gesellschaft. 2022; (20): 59–90.

4. Muntyanu A., Gabrielli S., Donovan J., et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. Journal of the European Academy of Dermatology and Venereology. 2023; (37): 1490–1520.

5. Craiglow B.G., King B.A. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal of the American Academy of Dermatology. 2019; 80 (2): 568–570.

6. Dai Y.X., Chen C.C. Tofacitinib therapy for children with severe alopecia areata // Journal of the American Academy of Dermatology. 2019; 80 (4): 1164–1166.

7. Waśkiel-Burnat A., Kotowska M., Dorobek W., et al. Therapeutic management in paediatric alopecia areata: a systematic review. Pediatric Dermatology. 2021.; (38): 1051–1063.

8. Patel V., Guttman-Yassky E., Castelo-Soccio L., et al. A clinician’s guide to pediatric and adolescent alopecia areata treatments. JAAD Reviews. 2024. Online ahead of print.

9. Rudnicka L., Rakowska A., Olszewska M., et al. European expert consensus statement on the systemic treatment of alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2024; 38 (2). Article ID e19768.

10. Messenger A.G., McKillop J., Farrant P., et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British Journal of Dermatology. 2012. (166): 916–926.

11. Rossi A., Muscianese M., Piraccini B.M., et al. Italian Guidelines in diagnosis and treatment of alopecia areata // Giornale Italiano di Dermatologia e Venereologia. 2019; (154).: 609–623.

12. Rakowska A., Rudnicka L., Olszewska M., et al. Alopecia areata: Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatology Review. 2023; (110): 89–100.

13. Lyakhovitsky A., Gilboa S., Eshkol A., et al. Late-onset alopecia areata: a retrospective cohort study. Dermatology. 2017; (233): 289–294.

14. Holmes S., Harries M., Macbeth A.E., et al. Alopecia areata and risk of atopic and autoimmune conditions. Clinical and Experimental Dermatology. 2023; (48): 325–331.

15. Kridin K., Renert-Yuval Y., Guttman-Yassky E., Cohen A.D. Alopecia areata is associated with atopic diathesis. Journal of Allergy and Clinical Immunology: In Practice. 2020; (8): 1323–1328.e1.

16. King B., Mostaghimi A., Shimomura Y., et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 2023; (188): 218.

17. Baricitinib – Pediatric Drug Information. UpToDate. 2024. 18. Tofacitinib – Drug Information. UpToDate. 2024.

18. Messenger A.G., McKillop J., Farrant P., et al. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. British Journal of Dermatology.– 2012; (166): 916–926

19. Alopecia areata: Clinical manifestations and diagnosis. UpToDate. 2024.

20. Goh C., Finkel M., Christos P.J., Sinha A.A. Profile of 513 patients with alopecia areata // Journal of the European Academy of Dermatology and Venereology. 2006; (20): 1055–1060.

21. Hubiche T., Leaute-Labreze C., Taieb A., et al. Poor long-term outcome of severe alopecia areata in children. British Journal of Dermatology. 2008; (158): 1136–1137.

22. Madani S., Shapiro J. Alopecia areata update. Journal of the American Academy of Dermatology. 2000; (42): 549–566.

23. Lew B.L., Shin M.K., Sim W.Y. Acute diffuse and total alopecia: A new subtype. Journal of the American Academy of Dermatology. 2009; (60): 85–93.

24. Rakowska A., Sikora M., Olszewska M., Rudnicka L. Trichoscopy of alopecia areata: an update. Journal of Dermatology. 2018; (45): 692–700.

25. Waśkiel-Burnat A. et al. Patients with alopecia areata are at risk of endothelial dysfunction. Clinical and Experimental Dermatology. 2022; (47): 1517–1522.

26. Conic R.R.Z., Chu S., Tamashunas N.L., et al. Prevalence of cardiac and metabolic diseases among patients with alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2021; (35): e128–129.

27. Korean Atopic Dermatitis and Alopecia Areata Guideline Committee. Guideline for diagnosis and treatment of alopecia areata in Korea. 2023.

28. Marks D.H., Mesinkovska N.A., Senna M.M. Review of dupilumab and alopecia areata. Journal of the American Academy of Dermatology. 2019.

29. The National Paediatric Alopecia Areata Registry in Russia. Journal of the American Academy of Dermatology. 2022.

30. Российские клинические рекомендации по очаговой алопеции. Минздрав РФ, 2022.

31. Castelo-Soccio L. Oral tofacitinib in adolescents with alopecia universalis. Journal of the American Academy of Dermatology. 2017; 6 (4): 754–755.

32. Craiglow B.G., Liu L.Y., King B.A. Tofacitinib for alopecia areata variants in adolescents. Journal of the American Academy of Dermatology. 2017; 76 (1): 29–32.

33. Brown L., Skopit S. Excellent response to tofacitinib in pediatric alopecia: a case report. Journal of Drugs in Dermatology. 2018; 17 (8): 914.

34. Patel N.U., Oussedik E., Grammenos A., et al. Effective treatment of alopecia universalis with tofacitinib. Journal of Cutaneous Medicine and Surgery. 2018; 22 (4): 439–442.

35. ALLEGRO Phase 2b/3 Study. Pfizer. Data on file, 2023.

36. EMA Summary of Product Characteristics: Olumiant (baricitinib). 2023.

37. FDA Approval Letter: Litfulo (ritlecitinib). 2023.

38. Alopeciaareata.pdf – Национальный регистр, Россия. 2022.

39. Korean Guideline. Clinical Dermatology Korea. 2023.

40. Rudnicka L., et al. Consensus – systemic treatment. Journal of the European Academy of Dermatology and Venereology. 2024.

41. King B., Zhang X., Gubelin Harcha W., Szepietowski J. C., Shapiro J., Lynde C., et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b 3 trial. The Lancet. 2023; 401 (10387): 1518–1529. DOI: 10.1016/S0140–6736(23)00486 2

42. Paller ES, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: a pooled analysis of the randomized clinical trials Measure Up 1, Measure Up 2, and AD Up. JAMA Dermatol. 2023; 159 (5): 526–535.

43. Российские клинические рекомендации по лечению АА.– Минздрав РФ, 2022

44. Yun D., Silverberg N. B., Stein S. L. Pediatric alopecia areata and hydroxychloroquine. Pediatric Dermatology. 2018; (35): 361–365.

45. Rakowska A., et al. Alopecia areata: Polish guidelines. Dermatology Review. 2023; (110): 89–100.

46. Barton V.R., Toussi A., Awasthi S., Kiuru M. Treatment of pediatric alopecia areata: A systematic review. Journal of the American Academy of Dermatology. 2022; 86 (6): 1318–1334. DOI: 10.1016/j.jaad.2021.04.077

47. Rosmarin D., et al. Two Phase 3 Trials of Ruxolitinib Cream for Vitiligo. New England Journal of Medicine. 2022; 387 (17): 1445–1455.

48. Kim B., et al. Ruxolitinib in pediatric patients with steroid-refractory graft-versus-host disease: a retrospective study. Pediatric Blood & Cancer. 2020; 67 (6): e28258.

49. Rajabi F., Drake L.A., Senna M.M., Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018. DOI: 10.1111/bjd.16808

50. Dainichi T., Kabashima K. Alopecia areata: What’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci. 2017; 86 (1): 3–12. DOI: 10.1016/j.jdermsci.2016.10.004.